Market News & Trends
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by US FDA for the Treatment of Relapsed or Recurrent Head & Neck Squamous Cell Carcinoma
AVEO Oncology recently announced the US FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head…
Carrick Therapeutics Debuts Data for First-In-Class Oral CDK7 Inhibitor Samuraciclib
Carrick Therapeutics recently presented encouraging initial clinical data on samuraciclib (CT-7001), an oral and first-in-class inhibitor of CDK7, at the 2021 European Society of Medical…
Cue Biopharma Granted US Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
Cue Biopharma, Inc. recently announced the issuance of two new United States Patents Nos. 11,117,945 and 11,104,712 from the United States Patent and Trademark Office.…
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration-Resistant Prostate Cancer
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111) in 80 men with metastatic castration-resistant prostate cancer…
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
ARCA biopharma, Inc. recently announced the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment…
Micropore Technologies Announced as a Winner in Heathrow Airport’s Global Britain Business Champion Competition
Micropore Technologies is a global business that has spent many hundreds of hours travelling across the world from London’s Heathrow Airport over recent years. This…
Catalent Signs Commercial Supply Agreement With Phathom Pharmaceuticals
Catalent recently announced it has signed a commercial supply agreement with Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments…
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
Excision BioTherapeutics, Inc. recently announced the US FDA has accepted the Investigational New Drug (IND) application for EBT-101, a CRISPR-based therapeutic candidate in development as…
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
Denali Therapeutics Inc. recently announced that dosing recently commenced in a Phase 1b study of DNL343, its brain-penetrant small molecule activator of EIF2B, in participants diagnosed…
Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate
Kinnate Biopharma Inc. recently announced results from preclinical studies evaluating its lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248. These findings were presented during…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….